Calidi Biotherapeutics will showcase data on its systemically delivered RedTail platform at the AACR‑IO conference in Los Angeles from February 18‑21, 2026. The presentation will focus on the company’s lead candidate, CLD‑401, engineered to express a high‑level IL‑15 superagonist and a tumor‑specific bispecific T‑cell engager (BiTE). The platform is designed to remodel the tumor microenvironment and enable T‑cell activation in solid tumors, a key challenge that has limited the success of BiTEs in these indications.
The presentation marks a significant operational milestone for Calidi, positioning the RedTail technology as a next‑generation approach for metastatic cancer treatment. By sharing preclinical data at a major oncology forum, the company aims to attract strategic partners and validate its platform’s potential, while also signaling progress toward an IND submission for CLD‑401 by the end of 2026.
Calidi’s financial profile reflects the typical profile of a clinical‑stage biotech: significant losses, a negative earnings‑per‑share of –$8.73, and a return on equity of –1,450.9%. The company has no revenue to date and relies on external funding and partnership agreements to support its development program. Despite these challenges, Calidi is actively pursuing collaborations to accelerate clinical progress and secure additional capital.
The company has described RedTail as a major leap forward in delivering genetic medicine via an engineered virus. It emphasizes that the platform’s ability to produce an IL‑15 superagonist and a BiTE directly within the tumor microenvironment could overcome the immunosuppressive barriers that have hindered solid‑tumor immunotherapies. This dual‑action strategy is intended to create a localized immune‑activating niche that supports sustained T‑cell engagement and tumor cell killing.
Overall, the AACR‑IO presentation represents a key step in Calidi’s development roadmap. Successful data disclosure could enhance the company’s attractiveness to investors and partners, potentially accelerating the path to clinical trials and eventual regulatory approval.
The content on EveryTicker is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.